Compare Pfizer Inc (PFE) vs Zillow Group Inc Class C (Z) Price & Performance

Pfizer (PFE) trades at $27.78, down 2.36% today, with a consensus price target of $28.33 suggesting modest upside. The stock shows mixed technical signals with bullish moving averages but neutral oscillators. Recent earnings have consistently beaten expectations, though revenue declined from pandemic peaks. The company maintains strong cash flow generation and a solid dividend yield of approximately 3.1%.

Pfizer presents a value opportunity with reasonable valuation metrics and dividend stability, but faces headwinds from post-COVID revenue normalization and patent expirations. The company's pipeline progress in obesity and oncology could drive future growth, though execution risks remain. Analyst sentiment leans cautious with 59% hold ratings.

Zillow Group (Z) trades at $32.36, down 6.45% amid a challenging housing market. The stock shows bearish technical signals with support at $30 and resistance at $34. Fundamentally, revenue growth continues (2025: $2.58B, 2026: $2.8B projected) with improving profitability (net margin turning positive at 1.96% in 2025). Recent Q2 2026 earnings beat expectations with $0.52 EPS versus $0.4459 expected, though the company faces regulatory scrutiny from a recent FTC settlement.

Despite near-term headwinds, Zillow's transition to an integrated transaction platform and strong rental market presence offer long-term growth potential. Key risks include housing market volatility, competitive pressures, and ongoing legal challenges. Analyst consensus price target of $52 suggests significant upside potential from current levels, though technical indicators remain bearish in the short term.